Penetration and effectiveness of antiretroviral therapy in the central nervous system

Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry

Volumn 8, Issue 2, 2009, Pages 169-183

  Letendre, Scott ^a   Ellis, Ronald J ^a   Best, Brookie ^b   Bhatt, Archana ^a   Marquie Beck, Jennifer ^a   LeBlanc, Shannon ^a   Rossi, Steven ^b   Capparelli, Edmund ^b   Allen McCutchan, J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiretrovirals; Cerebrospinal fluid; HIV; Pharmacology

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; VICRIVIROC; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CLINICAL TRIAL; COGNITIVE DEFECT; DEATH; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG METABOLISM; DRUG PENETRATION; DRUG RESPONSE; DRUG STRUCTURE; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LOW DRUG DOSE; NONHUMAN; PATIENT COMPLIANCE; PREVALENCE; PRIMARY PREVENTION; QUALITY OF LIFE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

EID: 73449096069     PISSN: 18715230     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152309789152057     Document Type: Review

References (100)

1. Dore, G. J.; Correll, P. K.; Li, Y.; Kaldor, J. M.; Cooper, D. A.; Brew, B. J. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS, 1999, 13(10), 1249-1253.
2. Deutsch, R.; Ellis, R. J.; McCutchan, J. A.; Marcotte, T. D.; Letendre, S.; Grant, I. AIDS-associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. AIDS, 2001, 15(14), 1898-1899.
3. Cysique, L. A.; Maruff, P.; Brew, B. J. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J. Neurovirol., 2004, 10(6), 350-357.
4. Tozzi, V.; Balestra, P.; Galgani, S.; Narciso, P.; Sampaolesi, A.; Antinori, A.; Giulianelli, M.; Serraino, D.; Ippolito, G. Changes in neurocognitive performance in a cohort of patients treated with HAART for 3 years. J. Acquir. Immune Defic. Syndr., 2001, 28(1), 19-27.
5. Tozzi, V.; Balestra, P.; Murri, R.; Galgani, S.; Bellagamba, R.; Narciso, P.; Antinori, A.; Giulianelli, M.; Tosi, G.; Fantoni, M.; Sampaolesi, A.; Noto, P.; Ippolito, G.; Wu, A. W. Neurocognitive impairment influences quality of life in HIV-infected patients receiving HAART. Int. J. STD AIDS, 2004, 15(4), 254-259.
6. Valcour, V.; Paul, R., HIV infection and dementia in older adults. Clin. Infect. Dis., 2006, 42(10), 1449-1454.
7. Sacktor, N.; Lyles, R. H.; Skolasky, R. L.; Anderson, D. E.; McArthur, J. C.; McFarlane, G.; Selnes, O. A.; Becker, J.; Cohen, B.; Wesch, J.; Miller, E. N. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men: Multicenter AIDS Cohort Study (MACS). Neurology, 1999, 52, 1640-1647.
8. Maschke, M.; Kastrup, O.; Esser, S.; Ross, B.; Hengge, U.; Hufnagel, A. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J. Neurol. Neurosurg. Psychiatr., 2000, 69(3), 376-380.
9. Ferrando, S. J.; Rabkin, J. G.; van Gorp, W.; Lin, S. H.; McElhiney, M. Longitudinal improvement in psychomotor processing speed is associated with potent combination antiretroviral therapy in HIV-1 infection. J. Neuropsychiatr. Clin. Neurosci., 2003, 15(2), 208-214.
10. Robertson, K. R.; Smurzynski, M.; Parsons, T. D.; Wu, K.; Bosch, R. J.; Wu, J.; McArthur, J. C.; Collier, A. C.; Evans, S. R.; Ellis, R. J. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS, 2007, 21(14), 1915-1921.
11. McCutchan, J. A.; Wu, J. W.; Robertson, K.; Koletar, S. L.; Ellis, R. J.; Cohn, S.; Taylor, M.; Woods, S.; Heaton, R.; Currier, J.; Williams, P. L. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS, 2007, 21(9), 1109-17.
12. Sevigny, J. J.; Albert, S. M.; McDermott, M. P.; Schifitto, G.; McArthur, J. C.; Sacktor, N.; Conant, K.; Selnes, O. A.; Stern, Y.; McClernon, D. R.; Palumbo, D.; Kieburtz, K.; Riggs, G.; Cohen, B.; Marder, K.; Epstein, L. G. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Archiv. Neurol., 2007, 64(1), 97-102.
13. Ellis, R. J.; Hsia, K.; Spector, S. A.; Nelson, J. A.; Heaton, R. K.; Wallace, M. R.; Abramson, I.; Atkinson, J. H.; Grant, I.; McCutchan, J. A. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann. Neurol., 1997, 42(5), 679-688.
14. Huisman, M. T.; Smit, J. W.; Hoetelmans, R. M.; Wiltshire, H. R.; Beijnen, J. H.; Schinkel, A. H. In The role of P-glycoprotein in oral bioavailability, brain and fetal penetration of the HIV protease inhibitor saquinavir, Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, United Kingdom, Glasgow, United Kingdom, 2000.
15. Wijnholds, J.; deLange, E. C.; Scheffer, G. L.; van den Berg, D. J.; Mol, C. A.; van der Valk, M.; Schinkel, A. H.; Scheper, R. J.; Breimer, D. D.; Borst, P. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Invest., 2000, 105(3), 279-285.
16. Wu, D.; Clement, J. G.; Pardridge, W. M. Low blood-brain barrier permeability to azidothymidine (AZT), 3TC, and thymidine in the rat. Brain Res., 1998, 791(1-2), 313-316.
17. Brewster, M. E.; Anderson, W. R.; Webb, A. I.; Pablo, L. M.; Meinsma, D.; Moreno, D.; Derendorf, H.; Bodor, N.; Pop, E. Evaluation of a brain-targeting zidovudine chemical delivery system in dogs. Antimicrob. Agents Chemother., 1997, 41(1), 122-128.
18. Staprans, S.; Marlowe, N.; Glidden, D.; Novakovic-Agopian, T.; Grant, R. M.; Heyes, M.; Aweeka, F.; Deeks, S.; Price, R. W. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS, 1999, 13(9), 1051-1061.
19. Price, R. W. The two faces of HIV infection of cerebrospinal fluid. Trends Microbiol., 2000, 8(9), 387-391.
20. Heaton, R. K.; Grant, I.; Butters, N.; White, D. A.; Kirson, D.; Atkinson, J. H.; McCutchan, J. A.; Taylor, M. J.; Kelly, M. D.; Ellis, R. J.; Wolfson, T.; Velin, R.; Marcotte, T. D.; Hesselink, J. R.; Jemigan, T. L.; Chandler, J.; Wallace, M.; Abramson, I.; and the HNRC Group. The HNRC 500 - neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J. Int. Neuropsychol. Soc., 1995, 1(3), 231-251.
21. Taylor, S.; Pereira, A. Penetration of HIV-1 protease inhibitors into CSF and semen. HIV Med., 2000, 1( Suppl 2), 18-22.
22. Sadler, B. M.; Gillotin, C.; Lou, Y.; Stein, D. S. In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob. Agents Chemother., 2001, 45(3), 852-856.
23. Anderson, P. L.; Brundage, R. C.; Bushman, L.; Kakuda, T. N.; Remmel, R. P.; Fletcher, C. V. Indinavir plasma protein binding in HIV-1-infected adults. AIDS, 2000, 14(15), 2293-2297.
24. Zhang, X. Q.; Schooley, R. T.; Gerber, J. G. The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors. J. Infect. Dis., 1999, 180(6), 1833-1837.
25. de Lange, E. C.; Danhof, M. Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain. Clin. Pharmacokinet., 2002, 41(10), 691-703.
26. Masereeuw, R.; Jaehde, U.; Langemeijer, M. W.; de Boer, A. G.; Breimer, D. D. In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors. Pharm. Res., 1994, 11(2), 324-330.
27. Enting, R. H.; Hoetelmans, R. M.; Lange, J. M.; Burger, D. M.; Beijnen, J. H.; Portegies, P. Antiretroviral drugs and the central nervous system. AIDS,1998, 12(15), 1941-1955.
28. Lee, C. G.; Gottesman, M. M.; Cardarelli, C. O.; Ramachandra, M.; Jeang, K. T.; Ambudkar, S. V.; Pastan, I.; Dey, S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry, 1998, 37(11), 3594-3601.
29. Rao, V. V.; Dahlheimer, J. L.; Bardgett, M. E.; Snyder, A. Z.; Finch, R. A.; Sartorelli, A. C.; Piwnica-Worms, D. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc. Natl Acad. Sci. USA, 1999, 96(7), 3900-3905.
30. Huisman, M. T.; Smit, J. W.; Wiltshire, H. R.; Hoetelmans, R. M.; Beijnen, J. H.; Schinkel, A. H. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol. Pharmacol., 2001, 59(4), 806-813.
31. Yazdanian, M. Blood-brain barrier properties of human immunodeficiency virus antiretrovirals. J. Pharmacol. Sci., 1999, 88(10), 950-954.
32. Groothuis, D. R.; Levy, R. M. The entry of antiviral and antiretroviral drugs into the central nervous system. J. Neurovirol., 1997, 3(6), 387-400.
33. Granero, L.; Santiago, M.; Cano, J.; Machado, A.; Peris, J. E. Analysis of ceftriaxone and ceftazidime distribution in cerebrospinal fluid of and cerebral extracellular space in awake rats by in vivo microdialysis. Antimicrob. Agents Chemother., 1995, 39(12), 2728-2731.
34. Jaruratanasirikul, S.; Hortiwakul, R.; Tantisarasart, T.; Phuenpathom, N.; Tussanasunthornwong, S. Distribution of azithromycin into brain tissue, cerebrospinal fluid, and aqueous humor of the eye. Antimicrob. Agents Chemoth., 1996, 40(3), 825-826.
35. Aamnoutse, R. E.; Verweij-van Wissen, C. P.; Underberg, W. J.; Kleinnijenhuis, J.; Hekster, Y. A.; Burger, D. M. High-performance liquid chromatography of HIV protease inhibitors in human biological matrices. J. Chromatogr. B. Biomed .Sci. Appl., 2001, 764(1-2), 363-384.
36. Haas, D. W.; Stone, J.; Clough, L. A.; Johnson, B. P. S.; Harris, V. L.; Nicotera, J.; Johnson, R. H.; Raffanti, S.; Zhong, L.; Bergqwist, P.; Chamberlin, S.; Hoagland, V.; Ju, W. D. Steady state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Clin. Pharmacol.Therap., 2000, 68(4), 367-374.
37. Haas, D. W.; Clough, L. A.; Johnson, B. W.; Harris, V. L.; Spearman, P.; Wilkinson, G. R.; Fletcher, C. V.; Fiscus, S.; Raffanti, S.; Donlon, R.; McKinsey, J.; Nicotera, J.; Schmidt, D.; Shoup, R. E.; Kates, R. E.; Lloyd, R. M. Jr.; Larder, B. Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma. AIDS Res. Hum. Retroviruses, 2000, 16(15), 1491-1502.
38. Capparelli, E. V.; Letendre, S. L.; Ellis, R. J.; Patel, P.; Holland, D.; McCutchan, J. A. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob. Agents Chemother., 2005, 49(6), 2504-2506.
39. Letendre, S. L.; Capparelli, E. V.; Ellis, R. J.; McCutchan, J. A. C. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. Antimicrob. Agents Chemother., 2000, 44(8), 2173-2175.
40. Shulman, N.; Zolopa, A.; Havlir, D.; Hsu, A.; Renz, C.; Boller, S.; Jiang, P.; Rode, R.; Gallant, J.; Race, E.; Kempf, D. J.; Sun, E. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrob. Agents Chemother., 2002, 46(12), 3907-3916.
41. Chaillou, S.; Durant, J.; Garraffo, R.; Georgenthum, E.; Roptin, C.; Clevenbergh, P.; Dunais, B.; Mondain, V.; Roger, P. M.; Dellamonica, P. Intracellular concentration of protease inhibitors in HIV-1-infected patients: correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin. Trials, 2002, 3(6), 493-501.
42. Descamps, D.; Flandre, P.; Calvez, V.; Peytavin, G.; Meiffredy, V.; Collin, G.; Delaugerre, C.; Robert-Delmas, S.; Bazin, B.; Aboulker, J. P.; Pialoux, G.; Raffi, F.; Brun-Vezinet, F. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA, 2000, 283(2), 205-211.
43. Burger, D.; Felderhof, M.; Phanupak, P.; Duncombe, C.; Mahanontharit, A.; Yeamwanichnun, W.; Ubolyam, S.; Cooper, D.; Stek, M.; Lange, J.; Reiss, P. In Both short-term virological efficacy and drug-associated nephrotoxicity are related to indinavir (IDV) pharmacokinetics (PK) in HIV-1-infected Thai patients, 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-8; Chicago, IL, 2001; p. 264.
44. Burger, D. M.; Hoetelmans, R. M.; Hugen, P. W.; Mulder, J. W.; Meenhorst, P. L.; Koopmans, P. P.; Brinkman, K.; Keuter, M.; Dolmans, W.; Hekster, Y. A. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antiviral Ther., 1998, 3(4), 215-220.
45. Back, D.; Gatti, G.; Fletcher, C.; Garaffo, R.; Haubrich, R.; Hoetelmans, R.; Kurowski, M.; Luber, A.; Merry, C.; Perno, C. F. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS, 2002, 16( Suppl 1), S5-37.
46. Marzolini, C.; Greub, G.; Decosterd, L.; Biollaz, J.; Telenti, A.; Buclin, T. In Routine antiretroviral plasma levels of NNRTIs and PIs correlate with viral suppression and adverse events, 8th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 4-8; Chicago, IL, 2001; p. 266.
47. Marzolini, C.; Telenti, A.; Decosterd, L. A.; Greub, G.; Biollaz, J.; Buclin, T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS, 2001, 15(1), 71-75.
48. Fletcher, C. V.; Kawle, S. P.; Kakuda, T. N.; Anderson, P. L.; Weller, D.; Bushman, L. R.; Brundage, R. C.; Remmel, R. P. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS, 2000, 14(14), 2137-244.
49. Powderly, W. G.; Saag, M. S.; Chapman, S.; Yu, G.; Quart, B.; Clendeninn, N.J. Predictors of optimal virological response to potent antiretroviral therapy. AIDS, 1999, 13, 1873-1880.
50. Yasuda, J. M.; Miller, C.; Currier, J. S.; Forthal, D. N.; Kemper, C. A.; Beall, G. N.; Tilles, J. G.; Capparelli, E. V.; McCutchan, J. A.; Haubrich, R. H. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antiviral Ther., 2004, 9(5), 753-761.
51. Acosta, E.; Havlir, D. V.; Richman, D. D. In Pharmacodynamics (PD) of indinavir (IDV) in protease-naive HIV-infected patients receiving ZDV and 3TC, 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 30-February 2; San Francisco, CA, 2000.
52. Best, B.; May, S.; Witt, M.; Kemper, C.; Larsen, R.; Diamond, C.; Heseltine, P.; He, F.; Capparelli, E.; McCutchan, A.; Haubrich, R. In Relationship between lopinavir (LPV) concentration and changes in lipid levels at 24 weeks, 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 8-11; San Francisco, CA, 2004.
53. Gonzalez de Requena, D.; Blanco, F.; Garcia-Benayas, T.; Jimenez-Nacher, I.; Gonzalez-Lahoz, J.; Soriano, V., Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS, 2003, 17(9), 443-445.
54. Miller, L.; McCutchan, J. A.; Keiser, P.; Kemper, C.; Witt, M.; Leedom, J.; Forthal, D.; Hellmann, N.; Richman, D.; Seefried, E.; Rigby, A.; Haubrich, R. Accumulation of antiretroviral resistance in treatment-experienced patients: the impact of medication adherence. Antiviral Ther., 2003, 8(Suppl 1), S418.
55. Bangsberg, D. R.; Moss, A. R.; Deeks, S. G. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J. Antimicrob. Chemother., 2004, 53(5), 696-699.
56. Bangsberg, D. R.; Porco, T. C.; Kagay, C.; Charlebois, E. D.; Deeks, S. G.; Guzman, D.; Clark, R.; Moss, A. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J. Infect. Dis., 2004, 190(1), 162-165.
57. King, M.; Brun, S.; Tschampa, J.; Moseley, J.; Kempf, D., Relationship between adherence and the development of viral resistance in antiretroviral-naive patients treated with lopinavir/ritonavir (lpv/r) or nelfinavir (nfv). Antiviral Ther., 2003, 8(Suppl 1), S408.
58. St Clair, M. H.; Richards, C. A.; Spector, T.; Weinhold, K. J.; Miller, W. H.; Langlois, A. J.; Furman, P. A. 3′-Azido-3′-deoxythymidine triphosphate as an inhibitor and substrate of purified human immunodeficiency virus reverse transcriptase. Antimicrob. Agents Chemother., 1987, 31(12), 1972-1977.
59. Richman, D. D.; Kornbluth, R. S.; Carson, D. A. Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages. J. Exp. Med., 1987, 166(4), 1144-1149.
60. Aquaro, S.; Perno, C. F.; Balestra, E.; Balzarini, J.; Cenci, A.; Francesconi, M.; Panti, S.; Serra, F.; Villani, N.; Calio, R. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J. Leukoc. Biol., 1997, 62(1), 138-43.
61. Perno, C. F.; Newcomb, F. M.; Davis, D. A.; Aquaro, S.; Humphrey, R. W.; Calio, R.; Yarchoan, R. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J. infect. Dis., 1998, 178(2), 413-422.
62. Rusconi, S.; Merrill, D. P.; Hirsch, M. S. Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy. J. Infect. Dis., 1994, 170(6), 1361-1366.
63. Spudich, S.; Lollo, N.; Liegler, T.; Deeks, S. G.; Price, R. W. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J. Infect. Dis., 2006, 194(12), 1686-1696.
64. Letendre, S.; Ellis, R.; McCutchan, J. Frequent Dissociation of Plasma and CSF HIV RNA Responses During Antiretroviral Therapy (Abstract 305). In 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000.
65. Ellis, R. J.; Gamst, A. C.; Capparelli, E.; Spector, S. A.; Hsia, K.; Wolfson, T.; Abramson, I.; Grant, I.; McCutchan, J. A. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology, 2000, 54(4), 927-936.
66. Foudraine, N. A.; Hoetelmans, R. M.; Lange, J. M.; de Wolf, F.; van Benthem, B. H.; Maas, J. J.; Keet, I. P.; Portegies, P. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet, 1998, 351(9115), 1547-1551.
67. Tashima, K. T.; Caliendo, A. M.; Ahmad, M.; Gormley, J. M.; Fiske, W. D.; Brennan, J. M.; Flanigan, T. P. Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J. infect. Dis., 1999, 180(3), 862-864.
68. Kravcik, S.; Gallicano, K.; Roth, V.; Cassol, S.; Hawley-Foss, N.; Badley, A.; Cameron, D. W. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J. Acquir. Immune Defic. Syndr., 1999, 21(5), 371-375.
69. Kravcik, S. Pharmacology and clinical experience with saquinavir. Expert Opin. Pharmacother., 2001, 2(2), 303-315.
70. Gisolf, E. H.; Enting, R. H.; Jurriaans, S.; de Wolf, F.; van der Ende, M. E.; Hoetelmans, R. M.; Portegies, P.; Danner, S. A. V. Cerebrospinal fluid HIV-1 RNA during treatment with ritonavir/saquinavir or ritonavir/saquinavir/ stavudine. AIDS, 2000, 14(11), 1583-1589.
71. Parkin, N. T.; Hellmann, N. S.; Whitcomb, J. M.; Kiss, L.; Chappey, C.; Petropoulos, C. J., Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob. Agents Chemother., 2004, 48(2), 437-443.
72. Letendre, S.; Marquie-Beck, J.; Capparelli, E.; Best, B.; Clifford, D.; Collier, A. C.; Gelman, B. B.; McArthur, J. C.; McCutchan, J. A.; Morgello, S.; Simpson, D.; Grant, I.; Ellis, R. J. Validation of the CNS penetration- effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch. Neurol., 2008, 65(1), 65-70.
73. Tozzi, V.; Balestra, P.; Salvatori, M.; Vlassi, C.; Liuzzi, G.; Menichetti, S.; Zaccarelli, M.; Cerilli, S.; Antinori, A.; Narciso, P. Changes in Cognition during HAART: Comparison of 2 Different Scoring Systems to Measure Antiretroviral Drug Efficacy on HIV Dementia (Abstract 391). In 15th Conference on Retroviruses and Opportunistic Infections, Boston, 2008.
74. Everall, I. P.; Vaida, F.; Letendre, S.; Lazzaretto, D.; Gelman, B. B.; Morgello, S.; Singer, E. J.; Masliah, E.; Grant, I. Reducing the Prevalence of Primary HIV Brain Pathology by Antiretrovirals (Abstract 67). In 15th Conference on Retroviruses and Opportunistic Infections, 2008.
75. Gasnault, J.; Lanoy, E.; Bentata, M.; Guiguet, M.; Costagliola, D. Intracerebral Penetrating ART Are More Efficient on Survival of HIV+ Patients with Progressive Multifocal Leucoencephalopathy (ANRS CO4 - FHDH) (Abstract 386). In 15th Conference on Retroviruses and Opportunistic Infections, Boston, 2008.
76. Letendre, S.; Ellis, R.; Cysique, L. A.; Cherner, M.; Gibson, S.; Heaton, R.; McCutchan, J. Low-grade Immune Restoration Disease May Limit Recovery from HIV-associated Neurocognitive Impairment (Abstract 68). In 15th Conference on Retroviruses and Opportunistic Infections, Boston, 2008.
77. Ellis, R. J. Clinical trials in HIV CNS disease and treatment management. J. Neuroimmune Pharmacol., 2007, 2(1), 20-5.
78. May, S.; Letendre, S.; Haubrich, R.; McCutchan, J. A.; Heaton, R.; Capparelli, E.; Ellis, R. Meeting practical challenges of a trial involving a multitude of treatment regimens: an example of a multi-center randomized controlled clinical trial in neuroAIDS. J. Neuroimmune Pharmacol., 2007, 2(1), 97-104.
79. Ellis, R.; Letendre, S.; Clifford, D.; Sacktor, N.; McCutchan, J. Cognitive Intervention Trial 2 (ClinicalTrials.gov identifier NCT00624195). http://clinicaltrials.gov/ct2/show/NCT00624195
80. Letendre, S.; Ellis, R.; Grant, I.; McCutchan, J. The CSF Concentration/ IC50 Ratio: A Predictor of CNS Antiretroviral (ARV) Efficacy (Abstract 614). In 8th Conference on Retroviruses and Opportunistic Infections, Chicago, 2001.
81. Antinori, A.; Perno, C. F.; Giancola, M. L.; Forbici, F.; Ippolito, G.; Hoetelmans, R. M.; Piscitelli, S. C. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin. Infect. Dis., 2005, 41(12), 1787-1793.
82. von Giesen, H. J.; Adams, O.; Koller, H.; Arendt, G. Cerebrospinal fluid HIV viral load in different phases of HIV-associated brain disease. J. Neurol., 2005, 252(7), 801-807.
83. Letendre, S. L.; McCutchan, J. A.; Childers, M. E.; Woods, S. P.; Lazzaretto, D.; Heaton, R. K.; Grant, I.; Ellis, R. J. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann. Neurol., 2004, 56(3), 416-423.
84. Eggers, C.; Hertogs, K.; Sturenburg, H. J.; van Lunzen, J.; Stellbrink, H. J. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration. AIDS, 2003, 17(13), 1897-1906.
85. Solas, C.; Lafeuillade, A.; Halfon, P.; Chadapaud, S.; Hittinger, G.; Lacarelle, B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother., 2003, 47(1), 238-2343.
86. Marra, C. M.; Lockhart, D.; Zunt, J. R.; Perrin, M.; Coombs, R. W.; Collier, A. C. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology, 2003, 60(8), 1388-1390.
87. Lafeuillade, A.; Solas, C.; Halfon, P.; Chadapaud, S.; Hittinger, G.; Lacarelle, B., Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin. Trials, 2002, 3(1), 27-35.
88. Robertson, K. R.; Fiscus, S.; Robertson, W. T.; Meeker, R.; Hall, C. D. In CSF HIV RNA and CNS Penetrating Antiretroviral Regimens, 9th Conference on Retroviruses and Opportunistec Infections, University of North Carolina, Chapel Hill, University of North Carolina, Chapel Hill, 2002.
89. Antinori, A.; Giancola, M. L.; Grisetti, S.; Soldani, F.; Alba, L.; Liuzzi, G.; Amendola, A.; Capobianchi, M.; Tozzi, V.; Perno, C. F. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients. AIDS, 2002, 16(14), 1867-1876.
90. De Luca, A.; Ciancio, B. C.; Larussa, D.; Murri, R.; Cingolani, A.; Rizzo, M. G.; Giancola, M. L.; Ammassari, A.; Ortona, L. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology, 2002, 59(3), 342-347.
91. Gisolf, E. H.; van Praag, R. M.; Jurriaans, S.; Portegies, P.; Goudsmit, J.; Danner, S. A.; Lange, J. M.; Prins, J. M. Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J. Acquir. Immune. Defic. Syndr., 2000, 25(5), 426-433.
92. Murphy In Antiviral Activity and Pharmacokinetics of Amprenavir with or without Zidovudine/3TC in the Cerebral Spinal Fluid of HIV-Infected Adults, 7th CROI, San Fransisco, CA, San Fransisco, CA, 2000.
93. Antinori, A.; Larussa, D.; Cingolani, A.; Lorenzini, P.; Bossolasco, S.; Finazzi, M. G.; Bongiovanni, M.; Guaraldi, G.; Grisetti, S.; Vigo, B.; Gigli, B.; Mariano, A.; Dalle Nogare, E. R.; De Marco, M.; Moretti, F.; Corsi, P.; Abrescia, N.; Rellecati, P.; Castagna, A.; Mussini, C.; Ammassari, A.; Cinque, P.; d'Arminio Monforte, A. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin. Infect. Dis., 2004, 39(11), 1681-1691.
94. Cysique, L. A.; Maruff, P.; Brew, B. J. Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch. Neurol., 2004, 61(11), 1699-1704.
95. Evers, S.; Rahmann, A.; Schwaag, S.; Frese, A.; Reichelt, D.; Husstedt, I. W. Prevention of AIDS dementia by HAART does not depend on cerebrospinal fluid drug penetrance. AIDS Res. Hum. Retroviruses, 2004, 20 (5), 483-491.
96. Robertson, K. R.; Robertson, W. T.; Ford, S.; Watson, D.; Fiscus, S.; Harp, A. G.; Hall, C. D. Highly active antiretroviral therapy improves neurocognitive functioning. J. Acquir. Immune Defic. Syndr., 2004, 36(1), 562-566.
97. Sevigny, J. J.; Albert, S. M.; McDermott, M. P.; McArthur, J. C.; Sacktor, N.; Conant, K.; Schifitto, G.; Selnes, O. A.; Stern, Y.; McClernon, D. R.; Palumbo, D.; Kieburtz, K.; Riggs, G.; Cohen, B.; Epstein, L. G.; Marder, K. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology, 2004, 63(11), 2084-2090.
98. Chang, L.; Ernst, T.; Witt, M. D.; Ames, N.; Walot, I.; Jovicich, J.; DeSilva, M.; Trivedi, N.; Speck, O.; Miller, E. N. Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART. Antiviral. Ther., 2003, 8(1), 17-26.
99. Dougherty, R. H.; Skolasky, R. L. Jr.; McArthur, J. C. Progression of HIV-associated dementia treated with HAART. AIDS Read., 2002, 12(2), 69-74.
100. Sacktor, N.; Tarwater, P. M.; Skolasky, R. L.; McArthur, J. C.; Selnes, O. A.; Becker, J.; Cohen, B.; Miller, E. N. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology, 2001, 57(3), 542-544.